|
|||||
|
|
Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma |
|
| Authors: | Jeng-Fong Chiou Cheng-Jeng Tai Ming-Te Huang Po-Li Wei Yu-Huei Wang Jane An Chih-Hsiung Wu Tsan-Zon Liu Yu-Jia Chang |
| Affiliation: | (1) Department of Radiation Oncology, Taipei Medical University and Hospital, Taipei, Taiwan;(2) Cancer Center, Taipei Medical University and Hospital, Taipei, Taiwan;(3) New York Medical College, Valhalla, NY, USA;(4) Department of Surgery, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan;(5) Department of Surgery, Taipei Medical University and Hospital, Taipei City, Taiwan; |
| Abstract: | BackgroundSorafenib is a newly established cancer drug found to be an effective systemic treatment for advanced hepatocellular carcinoma (HCC). However, little is known about any potential effectors that modify tumor cell sensitivity towards sorafenib. Here, we present the first evidence that glucose-regulated protein 78 (GRP78) is intimately associated with acquisition of resistance towards sorafenib. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |